NARA presses USTR on China testing barriers for rendered exports

The North American Renderers Association is using the Trump administration’s new U.S.-China Board of Trade process to press for a narrower, technical fix with broad commercial consequences: more transparent, science-based handling of Salmonella testing on U.S. rendered animal protein exports entering China. In comments to the Office of the United States Trade Representative, NARA said member companies have faced repeated situations in which non-ruminant animal protein meal shipments were flagged positive at certain Chinese ports, while retained production samples from the same lots tested negative through accredited laboratory methods. (ustr.gov)

The filing lands during a new phase in U.S.-China trade policy. USTR announced on June 2, 2026, that it was seeking public comment on the scope and operation of a proposed U.S.-China Board of Trade, described as an ongoing government-to-government channel to manage bilateral trade and consider tariff modifications for non-sensitive goods. The Federal Register notice frames the mechanism as a way to promote reciprocity, durability, and balance in the trade relationship, while still relying on tariffs and other tools where needed. (ustr.gov)

Against that backdrop, NARA’s comments focus less on tariffs than on non-tariff barriers. According to the industry summary of the filing, the association asked USTR to pursue greater transparency in China’s testing procedures, establish validated laboratory protocols, create a formal dispute-resolution process when results conflict, recognize equivalent industry quality assurance programs, and encourage regular technical consultations between regulators and industry representatives. Dana Johnson Downing, NARA’s senior vice president of international programs, said science-based regulatory practices and transparent testing procedures are essential for confidence in international markets and fair treatment of U.S. exporters. (nationalhogfarmer.com)

That position fits squarely within NARA’s broader trade agenda. The association says exports of U.S. rendered products support livestock, poultry, aquaculture, and pet food production worldwide, and that nearly 20% of U.S. rendered products are exported each year. China is listed among the industry’s top export markets, and an industry release described it as the sector’s third-largest export destination. NARA also points to its long-running Animal Protein Producers Industry program, founded in 1984, as a coordinated Salmonella testing and quality assurance framework for rendered animal proteins. (nara.org)

While outside expert reaction appears limited so far, the available trade and industry commentary suggests stakeholders see the Board of Trade docket as a meaningful opening to raise product-specific barriers that may not be solved through tariff policy alone. Trade advisers analyzing the June 2026 notice have described the process as a chance for exporters to argue for lower Chinese tariff treatment and for operational mechanisms that make bilateral trade more workable. In that sense, NARA’s submission is notable because it brings sanitary testing consistency, laboratory validation, and dispute resolution into a forum that might otherwise be dominated by tariff requests. (bhfs.com)

Why it matters: For veterinarians and animal health professionals, the story is upstream, but relevant. Rendered proteins sit inside a larger feed, ingredient, and pet food ecosystem, and disruptions tied to import testing can ripple through supply chains that ultimately affect formulation flexibility, ingredient costs, and sourcing stability. The issue also touches a familiar veterinary principle: when pathogen testing drives regulatory action, confidence in sampling methods, lab validation, and reproducibility matters. NARA is effectively arguing that inconsistent border findings can become a trade barrier if they aren’t backed by transparent, reproducible methods. That has implications not just for exporters, but for any sector that depends on predictable movement of animal-derived ingredients. (nationalhogfarmer.com)

There’s also a policy signal here. USTR’s notice specifically asks stakeholders how the Board of Trade should function, how it should modify product scope over time, and what data-sharing mechanisms are needed for the system to work. NARA’s recommendations map neatly onto those questions by proposing more formal technical engagement and a process for resolving conflicting test outcomes. If USTR adopts that framing, the result could be a more structured path for handling sanitary and phytosanitary friction in animal ingredient trade with China. (ustr.gov)

What to watch: The immediate milestone is July 10, 2026, when initial comments to docket USTR-2026-0430 are due, followed by a July 27 deadline for rebuttals and responses. After that, the key question is whether USTR treats testing transparency and technical dispute resolution as central Board of Trade design issues, or leaves them to separate regulatory channels. (ustr.gov)